Chemomab Therapeutics
CMMB
15 hedge funds and large institutions have $552K invested in Chemomab Therapeutics in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
7% more funds holding
Funds holding: 14 → 15 (+1)
1.09% less ownership
Funds ownership: 5.97% → 4.88% (-1.1%)
22% less capital inflows, than outflows
Capital inflows: $90.5K | Capital outflows: $116K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SmartHarvest Portfolios
Poulsbo,
Washington
|
+$24.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23K |
| 3 |
Kestra Private Wealth Services
Austin,
Texas
|
+$17.1K |
| 4 |
GAMMA Investing
Foster City,
California
|
+$8.65K |
| 5 |
Morgan Stanley
New York
|
+$1.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$67.7K |
| 2 |
Jane Street
New York
|
-$25.7K |
| 3 |
Virtu Financial
New York
|
-$18K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.84K |
| 5 |
XTX Topco
George Town,
Cayman Islands
|
-$656 |
CMMB Hedge Fund Activity: Q1 2026 in Review
15 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q1 2026, worth a combined $552K — down 8.9% from $606K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CMMB positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 3 trimmed.
The largest buyer was SmartHarvest Portfolios, opening a new position worth an estimated $24.9K. The largest seller was Citadel Advisors, cutting an estimated $67.7K.
- 15 institutional investors held Chemomab Therapeutics (CMMB) as of Q1 2026, up from 14 in Q4 2025.
- Funds reported $552K of Chemomab Therapeutics stock for Q1 2026, down 8.9% quarter-over-quarter.
- 4 funds opened new Chemomab Therapeutics positions in Q1 2026 and 3 closed out, a net change of +1 holder.
- The largest Chemomab Therapeutics buyer in Q1 2026 was SmartHarvest Portfolios, an estimated $24.9K added.
- The largest Chemomab Therapeutics seller in Q1 2026 was Citadel Advisors, an estimated $67.7K sold.
Based on aggregated 13F filings for Q1 2026.